Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the ...

Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the ...

On Wednesday, RBC Capital adjusted its outlook on Gilead Sciences (NASDAQ:GILD), increasing the price target to $74 from $72 while maintaining a Sector Perform rating. The revision follows ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of the ...

Gilead Sher is the founding senior partner in Gilead Sher & Co Law offices where he practices corporate law, project finance, administrative and constitutional law and dispute resolution. He is the ...

Gilead Sciences (NASDAQ:GILD) shares traded in the green on Tuesday, making it the seventh consecutive days of gains. The stock closed up 0.04% at $76.99. GILD stock fell about 0.06% in the last ...

In many ways, Yuhan Su represents the voice of the new generation of jazz musicians. Though she is firmly rooted in jazz tradition, her music is innovative, emotional, cerebral and most importantly, ...